These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37525483)

  • 21. Acute Kidney Injury Due to Ovarian Hyperstimulation Syndrome.
    Abou Arkoub R; Xiao CW; Claman P; Clark EG
    Am J Kidney Dis; 2019 Mar; 73(3):416-420. PubMed ID: 30600106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case report of Ovarian hyperstimulation syndrome and corpus luteum rupture in twin pregnancies with IVF-ET.
    Luo Y; Shen H; Li H; Tan Z; Chen C; Chen W; He J
    Medicine (Baltimore); 2023 Jul; 102(27):e34238. PubMed ID: 37417637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
    Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
    Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Jul; 34(7):616-622. PubMed ID: 29334275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volume expanders for the prevention of ovarian hyperstimulation syndrome.
    Youssef MA; Mourad S
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001302. PubMed ID: 27577848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous abdominal paracentesis for management of late type severe ovarian hyperstimulation syndrome.
    Chan CC; Yin CS; Lan SC; Chen IC; Wu GJ
    J Chin Med Assoc; 2004 Apr; 67(4):197-9. PubMed ID: 15244020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.
    Fiedler K; Ezcurra D
    Reprod Biol Endocrinol; 2012 Apr; 10():32. PubMed ID: 22531097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prednisone combined with letrozole reduced risk of ovarian hyperstimulation syndrome (OHSS) in women undergoing long-term gonadotropin-releasing hormone analog treatment.
    Fang L; Ruan M; Yang S; Qu X; Chen H; Zhao J; Cheng J
    Ann Palliat Med; 2021 Aug; 10(8):8837-8847. PubMed ID: 34488372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian hyperstimulation syndrome: A review for emergency clinicians.
    Timmons D; Montrief T; Koyfman A; Long B
    Am J Emerg Med; 2019 Aug; 37(8):1577-1584. PubMed ID: 31097257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?
    Ndukwe G; Thornton S; Fishel S; Dowell K; Aloum M
    Fertil Steril; 1997 Nov; 68(5):851-4. PubMed ID: 9389814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.
    Luke B; Brown MB; Morbeck DE; Hudson SB; Coddington CC; Stern JE
    Fertil Steril; 2010 Sep; 94(4):1399-1404. PubMed ID: 19591989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Update on ovarian hyperstimulation syndrome].
    Delbaere A; Rodesch C; Englert Y
    Rev Med Brux; 1995 Nov; 16(5):354-60. PubMed ID: 7501911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    D'Angelo A; Amso N
    Cochrane Database Syst Rev; 2002; (3):CD002811. PubMed ID: 12137659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS).
    Farkas B; Boldizsar F; Bohonyi N; Farkas N; Marczi S; Kovacs GL; Bodis J; Koppan M
    J Ovarian Res; 2020 Mar; 13(1):25. PubMed ID: 32138790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sudden Death Due to Severe Ovarian Hyperstimulation Syndrome: An Autopsy-Centric Case Report.
    Wang N; Chen Z; Guo X; Cheng H; Wang P; Wang T; Wang L; Tash D; Ren P; Zhu B; Guan D; Zhang G; Zhao R
    Am J Forensic Med Pathol; 2021 Mar; 42(1):88-91. PubMed ID: 33186129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of gestational hypertension in pregnancies complicated with ovarian hyperstimulation syndrome.
    Dobrosavljevic A; Rakic S
    J Pak Med Assoc; 2020 Nov; 70(11):1897-1900. PubMed ID: 33341826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and management of ovarian hyperstimulation syndrome.
    Chen CD; Chen SU; Yang YS
    Best Pract Res Clin Obstet Gynaecol; 2012 Dec; 26(6):817-27. PubMed ID: 22647872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.
    Baumgarten M; Polanski L; Campbell B; Raine-Fenning N
    Hum Fertil (Camb); 2013 Sep; 16(3):168-74. PubMed ID: 24047196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model.
    Jiang S; Li W; Zhao X; Chen L; Kuang Y
    Drug Des Devel Ther; 2022; 16():397-411. PubMed ID: 35221672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.